Stockscreener 앱 받기
2.28
1.30%
-0.03
시간 외 거래:
2.28
전일 마감가:
$2.31
열려 있는:
$2.28
하루 거래량:
28,175
Relative Volume:
0.85
시가총액:
$24.78M
수익:
$56.60M
순이익/손실:
$-34.12M
주가수익비율:
-0.4973
EPS:
-4.5844
순현금흐름:
$-1.36M
1주 성능:
+7.55%
1개월 성능:
-2.98%
6개월 성능:
-16.02%
1년 성능:
+22.58%
1일 변동 폭
$2.21
$2.29
1주일 범위
$2.10
$2.35
52주 변동 폭
$1.6501
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, TEVA, HLN, ZTS, VTRS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.28 | 24.78M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Lake Street | Buy |
| 2025-06-30 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Conferencia de resultados del cuarto trimestre fiscal de 2026 de Aytu BioPharma (AYTU): crecimiento de EXXUA y perspectivas para el ejercicio fiscal 2027 - TradingKey
Teleconferência de Resultados do 4º Trimestre Fiscal de 2026 da Aytu BioPharma (AYTU): Crescimento do EXXUA e Perspectivas para o Ano Fiscal de 2027 - TradingKey
Aytu BioPharma, Inc. (AYTU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary - Yahoo Finance
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.105 - TradingKey
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EX - GuruFocus
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... - Yahoo Finance
AYTU Looks 147.8% Overvalued on GF Value™ - GuruFocus
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% - Investing.com Nigeria
Is Aytu BioPharma Inc (AYTU) Worth the Investment After Q4 Resul - GuruFocus
AYTU: EXXUA prescriptions and revenue surged in Q4, driving positive adjusted EBITDA and cash stability - TradingView
Aytu BioPharma Narrows Fiscal 2026 Loss to $14.3 Million as EXXUA Debuts - Minichart
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast - Investing.com
AYTU: EXXUA momentum drove Q4 revenue growth and positive EBITDA, with FY27 set for further investment - TradingView
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% By Investing.com - Investing.com South Africa
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call - Benzinga
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth - TradingKey
AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary - TradingView
AYTU: EXXUA launch drove $6.6M in revenue, but overall sales fell 13% and net loss reached $14.3M - TradingView
New antidepressant adds revenue at Aytu BioPharma (NASDAQ: AYTU) as legacy drugs decline - Stock Titan
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
Aytu BioPharma reports FY2026 revenue $57.6M, Q4 revenue $16.1M and Adjusted EBITDA $0.5M - TradingView
Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million - Quiver Quantitative
AYTU: Q4 revenue rose 6.4% on EXXUA's launch, while full year revenue declined amid portfolio shifts - TradingView
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results - Voice of Alexandria
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan
AYTU Looks 154.9% Overvalued on GF Value™ - GuruFocus
AYTU Q4'26 Earnings: EPS estimate is (0.29) USD - TradingView
Aytu Biopharma Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M - scanx.trade
Aytu BioPharma will share yearly results Sept. 22 - Stock Titan
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 - ACCESS Newswire
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sets FY26, Q4 Results Date - TradingView
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st
AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds UpDividend Cut Risk - vinanet.vn
AYTU | AYTU BioPharma, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current UpdatePerformance Review - vinanet.vn
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsRisk Parity Rebalance - vinanet.vn
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69%Earnings Expansion Phase - vinanet.vn
Aytu Biopharma Inc (AYTU) Stock News Today - TradingKey
Aytu BioPharma, Inc. (0A8M.L) valuation measures and financial statistics - Yahoo Finance Australia
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key ResistanceDynamic Hedging - careplusvn.com
Aytu BioScience Inc (0A8M) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.69%
자본화:
|
볼륨(24시간):